Table 2.
Mean and Percentage of Baseline Levels Across Doses for Outcome Measures
| Baseline | Treatment | |||||
|---|---|---|---|---|---|---|
| 15 mg | 30 mg | 45 mg | 30 mg | 15 mg | ||
|
|
||||||
| Cigarettes/day | ||||||
| Mean (SD) | 26.6 (9.3) | 20.3 (9.1)* † | 16.3 (8.3)* † | 13.6 (8.3)* | 15.8 (10.5)* | 16.4 (10.5)* |
| % Baseline | – | 76.3 | 61.3 | 51.1 | 59.4 | 61.7 |
| CO (ppm) | ||||||
| Mean (SD) | 25.0 (7.9) | 21.4 (9.3)* † | 18.6 (10.2)* † | 15.7 (6.4)* | 17.0 (11.0)* | 16.5 (7.0)* |
| % Baseline | – | 85.6 | 74.4 | 62.8 | 68.0 | 66.0 |
| Cotinineabc | ||||||
| Mean (SD) | 7,170 (3,120) | – | – | 12,140 (5,690)* | – | 9,740 (6,070) |
| % Baseline | – | – | – | 169.3 | – | 135.8 |
| Total NNALabd | ||||||
| Mean (SD) | 2.50 (1.04) | – | – | 1.91 (.90)* | – | – |
| % Baseline | – | – | – | 76.1 | – | – |
Note. N = 20.
a
Quantities adjusted for urine concentration by dividing by creatinine level (mg).
b
Quantities not assessed at 15 and 30 mg time points.
c
(ng/mL).
d
(pmol/mL)
Significant differences between consecutive time points are shown with a dagger (†) while significant differences between treatment time points and baseline were shown with an asterisk (*).